Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy

PharmacoEconomics

Volumn 23, Issue 5, 2005, Pages 493-503

  Sheehy, Odile ^a   St Hilaire, Jean Marc ^a   Bernier, Giles ^a   Godfroid, Philippe ^b   LeLorier, Jacques J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; COMMON COLD; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSE CALCULATION; DRUG COST; DRUG WITHDRAWAL; EPILEPSY; FLU LIKE SYNDROME; FOCAL EPILEPSY; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MODEL; PHARYNGITIS; PRIORITY JOURNAL; RHINITIS; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTICONVULSANTS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; MODELS, ECONOMIC; PIRACETAM;

EID: 22244481601     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523050-00008     Document Type: Article

References (23)

1. Hauser WA, Annegers JF, Kurland L. Prevalence of epilepsy in Rochester, Minnesota. Epilepsia 1991; 32: 429-45
2. Cockerell OC, Johnson AL, Sander JWAS, et al. Prognosis of epilepsy: a review and further analysis of the first nine years of the British national general practice study of epilepsy, a prospective population-based study. Epilepsia 1997; 38: 31-46
3. Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999; 33: 39-55
4. Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of a patient-based and a population-based estimates. Neuroepidemiology 2000; 19: 87-99
5. Sander JW. New drugs for epilepsy. Curr Opin Neurol 1998; 11: 141-8
6. Levetircetam. Prescribing information [online]. Available from URL: http://www.keppra.com/hcp/Keppra_Full_PI.pdf [Accessed 2005 Mar 15]
7. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42
8. Shorvon SD, Löwenthal A, Janz D, et al. Multicenter, doubleblind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41 (9): 1179-86
9. Ben Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41 (10): 1276-83
10. Boon P, Chauvel, P, et al. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002; 48: 77-89
11. Guidelines for Economic Evaluations of Pharmaceuticals. 2nd ed. Ottowa: Canadian Coordinating Office for Health Technology Assessment, 1997 Nov
12. Privitera MD, Edrich P, Godfroid P. Dose-response relationship of levetiracetam. Eur J Neurol 2002; 9 Suppl. 2: 180-1
13. Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1998; 51: 1026-33
14. Leppik I, Morrell M, Bigdeli M, et al. Seizure-free days gained with levetiracetam in refractory epileptic patients. Neurology; 54 Suppl. 3: A307 P04.116
15. Leppik I, Morrell M, Godfroid P, et al. Seizure-free days gained with levetiracetam in refractory epileptic patients. Epilepsia 2003; 44 (10): 1351-3
16. Statistics Canada, Health Statistic Division. Hospital statistics: preliminary annual report 1994-1995. Ottawa: Ministry of Health 1996. Catalogue no. 83-241-XPB
17. Canadian Institute for Health Information (CIHI). DAD resource indicators for the use with complexity. Ottawa, ON: CIHI, 1999
18. Emergency visit: Ontario Health Association. Hospital and ministry, 1997-1998
19. Neurologist, non specialist visits: schedule of benefits, physician services under the health insurance act. 1998 Ontario, Ministry of Health [online]. Available from URL: http://health.gov.ca/english/providers/program/ ohip/sob/physserv/ a_ consul.pdf [Accessed 2004 Nov 11]
20. Patsalos PN. Pharmacokinetic profile of levetiracetam: towards ideal characteristics. Pharmacol Ther 2000; 85 (2): 77-85
21. Browne TR, Szabo GK, Leppik IE, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000; 40 (6): 590-5
22. US Keppra tablets and oral solution prescribing information and patient information, 2004 [online]. Available from URL: http://www.fda.gov/cder/foi/ label/1999/21035lbl/pdf [Accessed 2005 May 5]
23. Wiebe S, Gafni A, Blume WT, et al. An economic evaluation of surgery for temporal lobe epilepsy. J Epilepsy 1995; 8: 227-35